Jill Zouzoulas, M.D., FACR, describes the best practices for incorporating patient perspectives when determining the ideal route of administration for those with rheumatologic diseases.
Video content above is prompted by the following questions:
How do you evaluate the costs between IV vs. subcutaneous therapies when deciding which route of administration to use in patients?
Patient perspectives have been analyzed in those taking IV biologics for rheumatoid arthritis. What did the results show, and do they factor into your treatment decisions?